NU 98X3: IRINOTECAN (CPT-11) AND GEMCITABINE IN PATIENTS WITH SOLID TUMORS

NU 98X3：伊立替康 (CPT-11) 和吉西他滨治疗实体瘤患者

• 批准号: 7604237
• 负责人: AL B BENSON
• 金额: $ 0.59万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604237
• 关键词: NU; 98X3; IRINOTECAN; CPT; 11

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study involves treatment with two intravenous chemotherapy drugs: Irinotecan (CPT-11) and Gemcitabine. While both drugs have been utilized separately for the treatment of a wide variety of cancers, the best dose and schedule has yet to be determined when using them together. The purpose of this study is to discover the highest dose of CPT-11 that can be given safely with Gemcitabine.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究涉及两种静脉化疗药物：伊立替康(CPT-11)和吉西他滨。虽然这两种药物已经单独用于治疗各种癌症，但当它们联合使用时，最佳剂量和时间表尚未确定。这项研究的目的是发现与吉西他滨一起可以安全给予的CPT-11的最高剂量。